These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 9712784)
21. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen. Martinez LR; Moussai D; Casadevall A Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683 [TBL] [Abstract][Full Text] [Related]
22. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity. Netski D; Kozel TR Infect Immun; 2002 Jun; 70(6):2812-9. PubMed ID: 12010967 [TBL] [Abstract][Full Text] [Related]
23. Antibody to Cryptococcus neoformans capsular glucuronoxylomannan promotes expression of interleukin-12Rbeta2 subunit on human T cells in vitro through effects mediated by antigen-presenting cells. Vecchiarelli A; Pietrella D; Bistoni F; Kozel TR; Casadevall A Immunology; 2002 Jun; 106(2):267-72. PubMed ID: 12047756 [TBL] [Abstract][Full Text] [Related]
24. Scanning electron microscopy of encapsulated and non-encapsulated Cryptococcus neoformans and the effect of glucose on capsular polysaccharide release. Cleare W; Casadevall A Med Mycol; 1999 Aug; 37(4):235-43. PubMed ID: 10421858 [TBL] [Abstract][Full Text] [Related]
25. Cryptococcal glucuronoxylomannan inhibits adhesion of neutrophils to stimulated endothelium in vitro by affecting both neutrophils and endothelial cells. Ellerbroek PM; Hoepelman AI; Wolbers F; Zwaginga JJ; Coenjaerts FE Infect Immun; 2002 Sep; 70(9):4762-71. PubMed ID: 12183517 [TBL] [Abstract][Full Text] [Related]
34. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals. Deshaw M; Pirofski LA Clin Exp Immunol; 1995 Mar; 99(3):425-32. PubMed ID: 7882565 [TBL] [Abstract][Full Text] [Related]
35. The role of the complement anaphylatoxins in the recruitment of eosinophils. DiScipio RG; Schraufstatter IU Int Immunopharmacol; 2007 Dec; 7(14):1909-23. PubMed ID: 18039528 [TBL] [Abstract][Full Text] [Related]
36. T-cell-dependent and T-cell-independent mechanisms of tolerance to glucuronoxylomannan of Cryptococcus neoformans serotype A. Sundstrom JB; Cherniak R Infect Immun; 1993 Apr; 61(4):1340-5. PubMed ID: 8095924 [TBL] [Abstract][Full Text] [Related]
37. The polysaccharide capsule of Cryptococcus neoformans interferes with human dendritic cell maturation and activation. Vecchiarelli A; Pietrella D; Lupo P; Bistoni F; McFadden DC; Casadevall A J Leukoc Biol; 2003 Sep; 74(3):370-8. PubMed ID: 12949240 [TBL] [Abstract][Full Text] [Related]
38. Effects of anti-C5a antibodies on human polymorphonuclear leukocyte function: chemotaxis, chemiluminescence, and lysosomal enzyme release. Hatherill JR; Stephens KE; Nagao K; Ishizaka A; Wilmarth L; Wang JC; Deinhart T; Larrick JW; Raffin TA J Biol Response Mod; 1989 Dec; 8(6):614-24. PubMed ID: 2600603 [TBL] [Abstract][Full Text] [Related]
39. Colombo AC; Rella A; Normile T; Joffe LS; Tavares PM; de S Araújo GR; Frases S; Orner EP; Farnoud AM; Fries BC; Sheridan B; Nimrichter L; Rodrigues ML; Del Poeta M mBio; 2019 Apr; 10(2):. PubMed ID: 30940711 [No Abstract] [Full Text] [Related]
40. Immunoregulation by capsular components of Cryptococcus neoformans. Vecchiarelli A Med Mycol; 2000 Dec; 38(6):407-17. PubMed ID: 11204878 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]